Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 30, 2017

DrugPatentWatch Database Preview

Lacosamide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lacosamide and what is the scope of lacosamide freedom to operate?

Lacosamide
is the generic ingredient in two branded drugs marketed by Msn Labs Pvt Ltd, Mylan Pharms Inc, Sun Pharma Global, Amneal Pharms, Ucb Inc, Actavis Labs Fl Inc, Alembic Pharms Ltd, and Aurobindo Pharma Ltd, and is included in eleven NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lacosamide has nineteen patent family members in eleven countries.

There are twenty-one drug master file entries for lacosamide. Six suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for Generic Name: lacosamide

Tradenames:2
Patents:2
Applicants:8
NDAs:11
Drug Master File Entries: see list21
Suppliers / Packagers: see list6
Bulk Api Vendors: see list60
Clinical Trials: see list63
Patent Applications: see list976
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:lacosamide at DailyMed

Pharmacology for Ingredient: lacosamide

Tentative approvals for LACOSAMIDE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe10MG/MLSOLUTION;ORAL
► Subscribe► Subscribe200MGTABLET;ORAL
► Subscribe► Subscribe150MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-002Oct 28, 2008ABRXYesNoRE38551► SubscribeYY ► Subscribe
Mylan Pharms Inc
LACOSAMIDE
lacosamide
TABLET;ORAL205026-004Apr 28, 2016ABRXNoNo► Subscribe► Subscribe
Actavis Labs Fl Inc
LACOSAMIDE
lacosamide
TABLET;ORAL204855-003Apr 28, 2016ABRXNoNo► Subscribe► Subscribe
Msn Labs Pvt Ltd
LACOSAMIDE
lacosamide
TABLET;ORAL204921-004Apr 28, 2016ABRXNoNo► Subscribe► Subscribe
Actavis Labs Fl Inc
LACOSAMIDE
lacosamide
TABLET;ORAL204855-001Apr 28, 2016ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Formulary management
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot